Saccharomyces cerevisiae Sepsis Following Probiotic Therapy in an Infant.

A 3.5-month-old infant with undiagnosed underlying combined immunodeficiency presented with S. ceravisiae fungemia following treatment with S. boulardii containing probiotic preparation. This case highlights that the use of probiotics in sick patients may be fraught with danger.

Simultaneous hydrolysis and co-fermentation of whey lactose with wheat for ethanol production.

Whey permeate was used as a co-substrate to replace part of the wheat for ethanol production by Saccharomyces cerevisiae. The simultaneous saccharification and fermentation was achieved with ß-galactosidase added at the onset of the fermentation to promote whey lactose hydrolysis. Aspergillus oryzae and Kluyveromyces lactis ß-galactosidases were two enzymes selected and used in the co-fermentation of wheat and whey permeate for the comparison of their effectiveness on lactose hydrolysis. The possibility of co-fermentations in both STARGEN and jet cooking systems was investigated in 5L bioreactors. Ethanol yields from the co-fermentations of wheat and whey permeate were evaluated. It was found that A. oryzae ß-galactosidase was more efficient for lactose hydrolysis during the co-fermentation and that whey permeate supplementation can contribute to ethanol yield in co-fermentations with wheat.

Incorporation of whey permeate, a dairy effluent, in ethanol fermentation to provide a zero waste solution for the dairy industry.

This study proposes a novel alternative for utilization of whey permeate, a by-product stream from the dairy industry, in wheat fermentation for ethanol production using Saccharomyces cerevisiae. Whey permeates were hydrolyzed using enzymes to release fermentable sugars. Hydrolyzed whey permeates were integrated into wheat fermentation as a co-substrate or to partially replace process water. Cold starch hydrolysis-based simultaneous saccharification and fermentation was done as per the current industrial protocol for commercial wheat-to-ethanol production. Ethanol production was not affected; ethanol yield efficiency did not change when up to 10% of process water was replaced. Lactic acid bacteria in whey permeate did not negatively affect the co-fermentation or reduce ethanol yield. Whey permeate could be effectively stored for up to 4 wk at 4 °C with little change in lactose and lactic acid content. Considering the global abundance and nutrient value of whey permeate, the proposed strategy could improve economics of the dairy and biofuel sectors, and reduce environmental pollution. Furthermore, our research may be applied to fermentation strategies designed to produce value-added products other than ethanol.

Cultivation of oleaginous yeast using aqueous fractions derived from hydrothermal pretreatments of biomass.

This study addresses some of the current challenges in producing biofuels from yeast oils. Specifically, it valorizes byproduct waste streams of biomass processing technologies by integrating them as alternative carbon or nutrient sources in oleaginous yeast cultivation. Crude glycerol recovered from the thermal hydrolysis of various fats and oils was successfully used in culturing of the oleaginous yeast Cryptococcus curvatus, with growth and lipid accumulation occurring at levels identical to those achieved when commercially purchased glycerol was used. The aqueous byproduct stream from the hydrothermal processing of C. curvatus can also be recycled as a growth substrate for subsequent C. curvatus cultures. The addition of this stream promoted higher biomass production without affecting lipid accumulation and only moderately changing the fatty acid profile. Use of these recycling strategies reduces costs and environmental impact of current microbial biofuels production by providing accessible, non-expensive carbon sources and nutrients for oleaginous yeast cultivation.

Hydrothermal treatment of oleaginous yeast for the recovery of free fatty acids for use in advanced biofuel production.

Microbial oils hold great potential as a suitable feedstock for the renewable production of biofuels. Specifically, the use of oleaginous yeasts offers several advantages related to cultivation and quality of lipid products. However, one of the major bottlenecks for large-scale production of yeast oils is found in the lipid extraction process. This work investigated the hydrothermal treatment of oleaginous yeast for hydrolysis and lipid extraction resulting in fatty acids used for biofuel production. The oleaginous yeast, Cryptococcus curvatus, was grown in 5 L bioreactors and the biomass slurry with 53±4% lipid content (dry weight basis) was treated at 280 °C for 1h with an initial pressure of 500 psi in batch stainless steel reactors. The hydrolysis product was separated and each of the resulting streams was further characterized. The hexane soluble fraction contained fatty acids from the hydrolysis of yeast triacylglycerides, and was low in nitrogen and minerals and could be directly integrated as feedstock into pyrolysis processing to produce biofuels. The proposed hydrothermal treatment addresses some current technological bottlenecks associated with traditional methodologies such as dewatering, oil extraction and co-product utilization. It also enhances the feasibility of using microbial biomass for production of renewable fuels and chemicals.

Heterotrophic growth and lipid accumulation of Chlorella protothecoides in whey permeate, a dairy by-product stream, for biofuel production.

This study proposes a novel alternative for the utilization of whey permeate, a by-product stream from the dairy industry, as the feedstock for the biomass and lipid production of the microalgae Chlorella protothecoides. Glucose and galactose from the pre-hydrolyzed whey permeate were used as main carbon sources in a base mineral media for establishing batch and fed batch cultures. Batch cultures reached a biomass production of 9.1±0.2g/L with a total lipid accumulation of 42.0±6.6% (dry weight basis), while in the fed batch cultures 17.2±1.3g/L of biomass with 20.5±0.3% lipid accumulation (dry weight basis) were obtained. A third strategy for the direct utilization of whey permeate was investigated by simultaneous saccharification and fermentation (SSF), wherein, 7.3±1.3g/L of biomass with 49.9±3.3% lipid accumulation (dry weight basis) was obtained in batch mode using immobilized enzyme.

Multiparameter behavioral analyses provide insights to mechanisms of cyanide resistance in Caenorhabditis elegans.

Environmental toxicants influence development, behavior, and ultimately survival. The nematode Caenorhabditis elegans has proven to be an exceptionally powerful model for toxicological studies. Here, we develop novel technologies to describe the effects of cyanide toxicity with high spatiotemporal resolution. Importantly, we use these methods to examine the genetic underpinnings of cyanide resistance. Caenorhabditis elegans that lack the EGL-9 oxygen sensing enzyme have been shown to be resistant to hydrogen cyanide (HCN) gas produced by the pathogen Pseudomonas aeruginosa PAO1. We demonstrate that the cyanide resistance exhibited by egl-9 mutants is completely dependent on the HIF-1 hypoxia-inducible factor and is mediated by the cysl-2 cysteine synthase, which likely functions in metabolic pathways that inactivate cyanide. Further, the expression of cysl-2 correlates with the degree of cyanide resistance exhibited in each genetic background. We find that each mutant exhibits similar relative resistance to HCN gas on plates or to aqueous potassium cyanide in microfluidic chambers. The design of the microfluidic devices, in combination with real-time imaging, addresses a series of challenges presented by mutant phenotypes and by the chemical nature of the toxicant. The microfluidic assay produces a set of behavioral parameters with increased resolution that describe cyanide toxicity and resistance in C. elegans, and this is particularly useful in analyzing subtle phenotypes. These multiparameter analyses of C. elegans behavior hold great potential as a means to monitor the effects of toxicants or chemical interventions in real time and to study the biological networks that underpin toxicant resistance.

Pre-natal/juvenile chlorpyrifos exposure associated with immunotoxicity in adulthood in Swiss albino mice.

Chlorpyrifos (CPF) is a widely used agricultural organophosphorus insecticide (OP). Epidemiological studies have reported that children living in an OP contaminated environment, showed altered immune function. However, there is a paucity of experimental evidence for CPF-induced toxicity in the developmental phases of immune system. The current studies sought to ascertain the effect of CPF on the developing immune system of mice. Swiss albino dams were exposed orally with 0, 0.3, and 3.0 mg CPF/kg/day from GD12 to PND7, and then pups were directly dosed with CPF (by gavage) through PND42. One week after the final dose of CPF (i.e. on PND49), immunotoxicities in these offspring were assessed. These analyses revealed that there were increases in Foxp3+CD25+CD4+ T-regulatory (Treg) cell frequency in the spleens of 3.0 mg CPF/kg/day-exposed female mice, but not in males. In contrast, the anti-sheep red blood cells IgM response was reduced in both genders. Moreover, splenic lymphoproliferative response to phytohemagglutinin (PHA), concanavalin A (ConA), and lipopolysaccharide (LPS), as well as interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-6 production following LPS stimulation decreased in mice of both sexes at higher CPF doses. Together, these findings suggest that developmental CPF exposure might cause immunosuppression in mice. Some of these outcomes might arise, in part, through a suppression of pro-inflammatory cytokine production and/or changes in the responsivity (specifically to mitogens) of lymphocytes in these hosts.

Microfluidics-enabled method to identify modes of Caenorhabditis elegans paralysis in four anthelmintics.

The discovery of new drugs is often propelled by the increasing resistance of parasites to existing drugs and the availability of better technology platforms. The area of microfluidics has provided devices for faster screening of compounds, controlled sampling/sorting of whole animals, and automated behavioral pattern recognition. In most microfluidic devices, drug effects on small animals (e.g., Caenorhabditis elegans) are quantified by an end-point, dose response curve representing a single parameter (such as worm velocity or stroke frequency). Here, we present a multi-parameter extraction method to characterize modes of paralysis in C. elegans over an extended time period. A microfluidic device with real-time imaging is used to expose C. elegans to four anthelmintic drugs (i.e., pyrantel, levamisole, tribendimidine, and methyridine). We quantified worm behavior with parameters such as curls per second, types of paralyzation, mode frequency, and number/duration of active/immobilization periods. Each drug was chosen at EC75 where 75% of the worm population is responsive to the drug. At equipotent concentrations, we observed differences in the manner with which worms paralyzed in drug environments. Our study highlights the need for assaying drug effects on small animal models with multiple parameters quantified at regular time points over an extended period to adequately capture the resistance and adaptability in chemical environments.

Overview of plant-derived vaccine antigens: Dengue virus.

This review highlights the advantages and current status of plant-derived vaccine development with special reference to the dengue virus. There are numerous problems involved in dengue vaccine development, and there is no vaccine against all four dengue serotypes. Dengue vaccine development using traditional approaches has not been satisfactory in terms of inducing neutralizing antibodies. Recently, these issues were addressed by showing a very good response to inducing neutralizing antibodies by plant-derived dengue vaccine antigens. This indicates the feasibility of using plant-derived vaccine antigens as a low-cost method to combat dengue and other infectious diseases. The application of new methods and strategies such as dendritic cell targeting in cancer therapy, severe acute respiratory syndrome, tuberculosis, human immune deficiency virus, and malaria might play an important role. These new methods are more efficient than traditional protocols. It is expected that in the near future, plant-derived vaccine antigens or antibodies will play an important role in the control of human infectious diseases.

Amplitude-modulated sinusoidal microchannels for observing adaptability in C. elegans locomotion.

In this paper, we present a movement-based assay to observe adaptability in Caenorhabditis elegans locomotion behavior. The assay comprises a series of sinusoidal microchannels with a fixed wavelength and modulating (increasing or decreasing) amplitude. The channel width is comparable to the body diameter of the organism. Worms are allowed to enter the channel from the input port and migrate toward the output port. Within channel sections that closely match the worm's natural undulations, the worm movement is relatively quick and steady. As the channel amplitude increases or decreases along the device, the worm faces difficulty in generating the propulsive thrust, begins to slow down and eventually fails to move forward. A set of locomotion parameters (i.e., average forward velocity, number and duration of stops, range of contact angle, and cut-off region) is defined for worm locomotion in modulated sinusoidal channels and extracted from the recorded videos. The device is tested on wild-type C. elegans (N2) and two mutants (lev-8 and unc-38). We anticipate this passive, movement-based assay can be used to screen nematodes showing difference in locomotion phenotype.

A microfluidic platform for high-sensitivity, real-time drug screening on C. elegans and parasitic nematodes.

This paper describes a new microfluidic platform for screening drugs and their dose response on the locomotion behavior of free living nematodes and parasitic nematodes. The system offers a higher sensitivity drug screening chip which employs a combination of existing and newly developed methods. Real-time observation of the entire drug application process (i.e. the innate pre-exposure locomotion, the transient response during drug exposure and the time-resolved, post-exposure behavior) at a single worm resolution is made possible. The chip enables the monitoring of four nematode parameters (number of worms responsive, number of worms leaving the drug well, average worm velocity and time until unresponsiveness). Each parameter generates an inherently different dose response; allowing for a higher resolution when screening for resistance. We expect this worm chip could be used as a robust cross species, cross drug platform. Existing nematode motility and migration assays do not offer this level of sophistication. The device comprises two principal components: behavioral microchannels to study nematode motility and a drug well for administering the dose and observing drug effects as a function of exposure time. The drug screening experiment can be described by three main steps: (i) 'pre-exposure study'- worms are inserted into the behavioral channels and their locomotion is characterized, (ii) 'dose exposure'- worms are guided from the behavioral microchannels into the drug well and held for a predefined time, during which time their transient response to the dose is characterized and (iii) 'post-exposure study'- worms are guided back into the behavioral microchannels where their locomotion (i.e. their time-resolved response to the dose) is characterized and compared to pre-exposure motility. The direction of nematodes' movement is reliably controlled by the application of an electric field within a defined range. Control experiments (e.g. in the absence of any drug) confirm that the applied electric fields do not affect the worms' motility or viability. We demonstrate the workability of the microfluidic platform on free living Caenorhabditis elegans (wild-type N2 and levamisole resistant ZZ15 lev-8) and parasitic Oesophagotomum dentatum (levamisole-sensitive, SENS and levamisole-resistant, LEVR) using levamisole (a well-studied anthelmintic) as the test drug. The proposed scheme of drug screening on a microfluidic device is expected to significantly improve the resolution, sensitivity and data throughput of in vivo testing, while offering new details on the transient and time-resolved exposure effects of new and existing anthelmintics.

BldG and SCO3548 interact antagonistically to control key developmental processes in Streptomyces coelicolor.

The similarity of BldG and the downstream coexpressed protein SCO3548 to anti-anti-sigma and anti-sigma factors, respectively, together with the phenotype of a bldG mutant, suggests that BldG and SCO3548 interact as part of a regulatory system to control both antibiotic production and morphological differentiation in Streptomyces coelicolor. A combination of bacterial two-hybrid, affinity purification, and far-Western analyses demonstrated that there was self-interaction of both BldG and SCO3548, as well as a direct interaction between the two proteins. Furthermore, a genetic complementation experiment demonstrated that SCO3548 antagonizes the function of BldG, similar to other anti-anti-sigma/anti-sigma factor pairs. It is therefore proposed that BldG and SCO3548 form a partner-switching pair that regulates the function of one or more sigma factors in S. coelicolor. The conservation of bldG and sco3548 in other streptomycetes demonstrates that this system is likely a key regulatory switch controlling developmental processes throughout the genus Streptomyces.